Ligand Pharmaceuticals (LGND) Q4 FY25 earnings call: guidance and Q&A

Beyond FILSPARI in FSGS, what other clinical updates should investors expect for late-stage assets in 2026?

Todd Davis highlighted a comprehensive list of active late-stage pipeline assets with expected updates in the coming quarters. These include Qarziba (U.S. approval, Ewing sarcoma), BOT/BAL (Phase 3), Orchestra's AVIM therapy and Virtue-SAB trials (Phase 3), Castle Creek's D-Fi (Phase 3), QTORIN rapamycin (mLM and cVM), lasofoxifene, and Tzield (T1D expansion). He noted that a significant majority of these assets were added in the last 2-2.5 years, indicating accelerating efforts to add more late-stage assets.

“I would just point out that a significant majority of these have been added into the portfolio in the last 2, 2.5 years. Those efforts are accelerating. You can expect additional late-stage assets to continue to be added into our pipeline.”

asked by Trevor Allred · answered by Todd Davis

Can you provide an update on monetizing older assets and potential for reinvigoration of the older pipeline?

Lauren Hay confirmed active engagement on 5-10 opportunities across the portfolio, some being new investments and others leveraging Ligand's operating capabilities (scientific, regulatory, commercial) to support partners. She expects another 10 opportunities to be engaged over the next couple of quarters, with potential for 1-2 public announcements by year-end, citing lasofoxifene as an example of a legacy investment yielding value.

“We have 5 to 10 opportunities across the portfolio where we're very actively engaged at the moment. Some of those would be new investment opportunities for Ligand. Others are opportunities where we do have operating capabilities on our senior team in terms of really a lot of depth and breadth of experience scientifically across the regulatory domain and then commercially where we could offer advice and support to our partners.”

asked by Matthew Hewitt · answered by Lauren Hay

Despite a low royalty, what is the larger market opportunity for Tzield, and what are its potential peak sales contributions to Ligand?

Lauren Hay explained that while Ligand's royalty on Tzield is low, Sanofi views it as a blockbuster opportunity. The current Stage 2 T1D indication targets presymptomatic patients, which is challenging to screen. However, the new indication for Stage 3 T1D (newly diagnosed symptomatic patients) is much larger and more commercially accessible. Sanofi has high conviction, and Ligand is eager for the decision on the Stage 3 indication in H1 2026.

“The one where they have the commissioner's voucher, that indication is in Stage 2 disease. Those are newly diagnosed symptomatic patients. Those are much more accessible commercially just because they're already in the health care system and being treated. Commercially, that opportunity is probably much larger.”

asked by Annabel Samimy · answered by Lauren Hay

How does the slight delay for FILSPARI FSGS approval impact the reiterated 2026 guidance range, and what was the assumed royalty contribution?

Octavio Espinoza stated that the impact is negligible, as the 2026 royalty guidance included a relatively modest, risk-adjusted assumption of $4 million contribution from FSGS. He noted that while the delay minimally impacts this number, a positive approval outcome would derisk the input and potentially lead to a higher contribution, but FSGS is expected to be a minor contributor in 2026, becoming more significant in later years.

“We assumed relatively -- we have a relatively modest assumption. It is a risk-adjusted number on FSGS going into the 2026 royalty guide. We did disclose that number. It's in our Investor Day slides. It's $4 million in 2026.”

asked by Joan Kim · answered by Octavio Espinoza

Given the strong deployable capital, have there been any changes or updates to the selection criteria for potential partnerships, such as deal size?

Todd Davis explained that as the portfolio's value grows, the average value per deal Ligand seeks will increase proportionately. He emphasized a focus on high clinical value assets, often with Phase 3 studies costing $30 million to $80 million, where there's high capital demand and fewer structured finance solutions. The goal is to achieve greater value generation and acceleration over time through a combination of slightly larger deals and more deals.

“As the value of our portfolio grows and it is growing rapidly, the average value per deal that we want to capture will go up proportionately. Just as a matter of functional strategy, you can increase proportionately your deal size or you can do more deals.”

asked by Joseph Pantginis · answered by Todd Davis

Can you discuss the potential differentiations of Castle Creek's D-Fi technology compared to Krystal's VYJUVEK, particularly regarding surface area addressed?

Lauren Hay highlighted that Castle Creek's D-Fi is a Phase 3 gene-modified autologous cell therapy for DEB, similar to VYJUVEK, but is injectable. This allows it to expand the body surface area treated, unlike VYJUVEK, which is a topical HSV vector limited to open wounds. She noted that VYJUVEK has validated the market with nearly $400 million in 2025 sales, and D-Fi could be a complementary treatment, especially for chronic wounds not accessible by topical applications, and potentially for hands and feet in the long term.

“The differentiation here is that it's injectable. It could expand the body surface area, whereas VYJUVEK has a live HSV vector and is applied topically. They're pretty limited in terms of the accessible body surface area for any individual patient.”

asked by Joseph Pantginis · answered by Lauren Hay

How are the current M&A and IPO market conditions affecting the opportunities Ligand sees?

Todd Davis stated that the market is generally 'okay' and better than two years ago. He emphasized that royalty financing is growing rapidly regardless of broader market conditions, having doubled in the last five years. It's now seen as a mainstream capital structure tool, offering advantages like long-term investments tied to asset life cycles. He noted that Ligand's pipeline of opportunities remains robust, with more deals available than they can pursue, allowing for aggressive culling to focus on high-probability, high-return assets.

“In good markets and in bad, I think royalty financing is growing rapidly regardless. It's doubled in the last 5 years. People are seeing it as much more a mainstream part of their capital structure for lack of a better term.”

asked by John Vandermosten · answered by Todd Davis